The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-driven, nonprofit organization that is dedicated to a simple but compelling vision and mission.
OUR VISION: A world without Waldenstrom’s macroglobulinemia (WM).
OUR MISSION: Support and educate everyone affected by WM to improve patient outcomes while advancing the search for a cure.
The IWMF is committed to creating a world without WM by finding a cure. Since 1999, the IWMF has invested over $31 million in WM research projects throughout the world. Thanks to this research, WM patients have better treatment options that can lead to deeper, longer lasting remissions, and fewer side effects.
September 22, 2021
Article
The FDA approval of Brukinsa represents another treatment option with fewer side effects in patients with Waldenstrom's macroglobulinema, however it will not serve as a replacement for other therapies.